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Pancreas divisum has been postulated as a cause of acute pancreatitis and a chronic pain syndrome
in a small subgroup ofpatients and can be treated with endoscopic dorsal pancreatic duct stent place-
ment and minor papilla sphincterotomy. Twenty patients (9 with at least one attack ofidiopathic pan-
creatitis, and 11 with severe pancreatic-type pain) were treated endoscopically. Dorsal duct stents
were placed in 19 patients with subsequent needle knife sphincterotomy of the minor papilla over
the stent. Clinical response was judged by comparison of symptoms (using a 0-to-l0 scale and the
patient’ s overall assessment). The symptom score improved from 9.3 to 5.1 in the pancreatitis group
and from 9.3 to 5.7 in the pain group. A good clinical response was observed in 3 of7 patients in the
pancreatitis group and in 6 of in the pain group at a mean follow-up of22 months. Complications
of sphincterotomy were limited to pancreatitis in 6 patients (29%), 5 mild and moderate according
to published criteria. No patient required more than 4 days hospitalization. Two of39 stents migrated
into the pancreas, and another stent fractured and remained lodged in the pancreas. Eight of 9 pa-
tients evaluated demonstrated new morphologic duct changes on follow-up pancreatograms.
Endoscopic stenting and sphincterotomy of the minor papilla are feasible and may be effective in
some patients with pancreas divisum but carries a significant complication rate. The subjective im-
provement in patients with chronic pain wan’ants further controlled study.
KEY WORDS: pancreas divisum, recurrent pancreatitis, endoscopic stenting, pancreatic
sphincterotomy
INTRODUCTION
Pancreas divisum is the mostcommon congenital malfor-
mation of the pancreas, arising when the embryonic dor-
sal and ventral anlagen fail to fuse in the usual manner. As
a result, most of the head and all of the body and tail of
the pancreas drain via the dorsal duct and through the
minor papilla. It is estimated from autopsy series that pan-
creas divisum is present in up to9% of the population (1).
Pancreas divisum has been proposed as a cause for acute
pancreatitis and apancreatic pain syndrome (2-3). This hy-
pothesis has been both supported and contradicted during
the past 10 years (4-7). The pathogenesis is assumed to be
a relative obstruction of pancreatic flow through the small
minor papilla.
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A variety of surgical and endoscopic interventions have
been performed to relieve the proposed ductal obstruction
and improve pancreatic drainage with variable to good re-
suits. (8-14). We report the technical feasibility, response
to therapy, and complications in a retrospective study in
which a combination of endoscopic stenting and sphinc-
terotomy ofthe minor papillawas performed in 20 patients
with symptomatic pancreas divisum.
PATIENTS AND METHODS
Our records from 1987 to 1991 were searched to identify
all patients with symptomatic pancreas divisum and had
undergone sphincterotomy of the minor papilla. Twenty-
one patients were identified, but one patient who was ul-
timately found to have carcinoma was excluded. The
remaining 20 patients (7 men and 13 women, mean age,
43.3 years) with symptomatic pancreas divisumwho were132 S.A. COHEN et al.
treated with pancreatic stenting and endoscopic sphinc-
terotomy of the minor papilla make up the basis of this
report. Four of these patients were included in an earlier
report (14). The diagnosis of pancreas divisum was es-
tablished by pancreatography in all patients. No patient
had been previously treated endoscopically or surgically.
Eight patients reported at least two documented attacks
ofpancreatitis, whereas patienthadone attack (4women
and 5 men, mean age, 50.7 years). Pancreatitis was de-
fined as severe abdominal pain associated with an eleva-
tion ofserum amylase to more than three times the normal
level or evidence of pancreatitis on computed tomogra-
phy (CT). The majority of these patients had frequent
episodes of epigastric pain that were similar in character
to, but were not, attacks of acute pancreatitis. Known
causes of pancreatitis were excluded including pancre-
atitis caused by gallstones, alcohol consumption, hyper-
triglyceridemia, hypercalcemia, medications, and
heredity. Six patients had had their gallbladders removed;
the remaining 3 patients did not have cholelithiasis by
sonography and cholangiography.
Eleven patients (9 women and 2 men, mean age, 36.5
years) had disabling pancreatic-type pain without pan-
creatitis ("pain-only" group). Serum amylase values were
normal or less than twice normal. The pancreas was nor-
mal by sonography or CT. All patients were thoroughly
evaluated to exclude other causes ofabdominal pain such
as cholelithiasis, choledocholithiasis, andpeptic ulcerdis-
ease. Four patients had intact gallbladders. Sphincter of
Oddi manometry was performed in 2 patients, and pres-
sures were within the normal range.
The general outline ofendoscopic treatmentwas as fol-
lows: endoscopic retrograde cholangiopancreatography
(ERCP) and stent placement at time zero; sphincterotomy
and stent exchange at 2 to 3 months; stent removal at 4 to
6 months.
Each patientunderwentERCP with visualization ofthe
biliary tree and usually the ventral pancreas. The dorsal
pancreatic duct was opacified (Fig. 1) in every patient
using a needle-tipped catheter (Wilson-Cook), to cannu-
late the minor papilla. No patient had dorsal changes sug-
gestive of chronic pancreatitis. A 0.035-inch guidewire
was inserted into the dorsal pancreatic duct via the minor
papilla (Figs 2 and 3), and when possible the orifice was
dilated with a tapered 4 to 7 French dilation catheter
(Wilson-Cook); 0.018 and 0.025-inch guidewires were
not employed. It was possible to place 5 or 7 French pan-
creatic stents in 17 of 20 patients; either strait "Geenen"
or C-loop "Siegel" stents, both with multiple side holes
were used (Wilson-Cook) (Figs 3 and 4). In 3 patients this
was not possible, and a de novo precut sphincterotomy
was performed using a needle-knife (Wilson-Cook)
(Fig. 5). One of these patients improved and required no
further intervention; the other 2 returned for successful
stent placement and extension of the sphincterotomy.
Eighteen patients returned after stent insertion and un-
derwentsphincterotomy oftheminorpapillawith the stent
in place (mean, 5.1 months; range, 1 to 22 months).A nee-
die-knife sphincterotome was used to cut 3 to 5 mm up-
ward and 2 to 3 mm deep in the 11 o’clock direction
exposing the pancreatic prosthesis (Fig. 6). The initial
stent then was removed and replaced with a new stent to
prevent restenosis of the orifice during healing. Removed
stents were almost all occluded. Placing a new stent pro-
vides pancreatic drainage despite the presence of inflam-
mation and edema that occur following sphincterotomy.
Pancreatic stents were removed, usually on a outpatient
basis, a mean of 3.6 months after insertion.
Hospital and office records were reviewed to determine
complications and hospital stay for all patients after
sphincterotomy of the minor papilla. Postprocedure com-
plications were defined according to the recent consensus
conference criteria (15). Patients were seen in follow-up
in the office or by the referring gastroenterologist under
our direction.
Follow-up for 18 of 20 patients was obtained by a sin-
gle interviewer not involved with the endoscopic proce-
dures or patient care. Patients were asked to classify pain
before and after therapy on a linear scale of 0 (none) to
10 (most severe). Patients also were asked to rate their re-
sponse to therapy by choosing from 5 adjectives: worse,
same, somewhat better, much better, or completely better.
"Somewhat better" was not considered a positive re-
sponse.
Radiographs obtained before and at the time of pan-
creatic stentremovalwere available for9 patients andwere
reviewed blindly by a radiologist for possible ductal
changes. No patient had follow-up pancreatograms after
stent removal.
A Pearson Z-
test was used to compare the proportion
of patient outcome between groups. A paired test was
used to compare the mean symptom scores of patients
within each group. The MANOVA test was used to ana-
lyze the variance of pre- and postprocedure symptom
scores of patients by group.
RESULTS
Follow-up was available for 18 patients (7 in the pancre-
atitis group, and 11 in the pain-only group) at a mean of
22 months after initial stent placement (range, 4 to 57
months). Five (71%) of7 patients in the pancreatitis group
clinically responded to initial stent placement, but after aENDOSCOPIC STENTING AND SPHINCTEROTOMY 133
Figure 1 Endoscopic retrograde pancreatogram demonstrating a dorsal pancreatic duct in a patient with pancreas divisum. Overfilling
of the tail is present.
mean of 13.7 months only 3 (43%) of 7 were "much bet-
ter" or "completely better". Eight (73%) of 11 patients in
the pain-only group gained reliefwith the initial stent, but
at mean follow-up of 25.4 months this decreased to 6
(55%) of 11 patients (Table 1). One of the 7 patients in
the pancreatitis group experienced an attack of pancreati-
tis. The mean symptom score after treatment was signif-
icantly reduced in both groups: 9.0+ 0.6 (+ standard error)
to 5.0 + 1.3 (p < 0.018) in the pancreatitis group, and 9.2
+ 0.3 to 4.5 + 1.1 (p < 0.001) in the pain-only group. There
was, however, no statistical difference in the clinical im-
provement between these two groups.
Table Symptomatic response to dorsal duct stenting and minor
papilla sphincterotomy in patients with pancreas divisum
Pancreatitis group Pain-only group
(N 7) (N I1)
better 2
Much better 5
Somewhat better 4 4
Same 0
Worse 0 0
Six (29%) of 21 patients undergoing sphincterotomy
experienced pancreatitis: 5 mild, moderate according to
published criteria (15). None of the 3 patients in the pre-
cut group experienced complications. However, the pan-
creatitis was mild, andno patientwas discharged later than
the fourth day. The mean hospital stay for all patients was
2.1 days (range, to 4). There were no severe complica-
tions of pancreatitis, i.e., phlegmon, abscess, pseudocyst,
or sepsis. Likewise, no other complications such as per-
foration or hemorrhage occurred, and there was no mor-
tality in this series.
A total of 39 stents were placed in 19 patients: 29 7
French stents varying in length from 5 to 7 cm, and 10 5
French stents usually 5 cm in length. Sixteen patients had
2 stents inserted during treatment, 2 patients had 3 stents,
and patient had a single stent. Stents migrated proxi-
mally into the pancreas in 2 patients (5.1%) of 39 stents.
One stent was retrieved endoscopically, the other surgi-
cally. One stent fractured during retrieval, with part of the
stent remaining lodged in the dorsal duct. The patientcon-
tinues to have attacks ofpancreatitis as before therapy and134 S.A. COHEN et al.
Figure 2 A radiograph demonstrating cannulation of the dorsal pancreatic duct with a 0.035-in guidewire and tapered 7 French dilating catheter in
the same patient.
refuses to undergo further intervention either endoscopic
or surgical.
Radiographs were available for comparison of ductal
changes in 9 patients prior to and at the time of stent re-
moval. Stents remained in place from 2 to 11 months. All
patients had normal pancreatograms before stenting.
Eight of these 9 patients demonstrated morphologic duct
changes on follow-up pancreatograms. All 8 patients had
increases in the diameter ofthe dorsal duct of at least75%,
2 patients demonstrated new strictures of the main pan-
creatic duct, and 7 patients had secondary branch changes.
DISCUSSION
The pathogenesis of acute pancreatitis and a pancreatic
pain syndrome in patients with pancreas divisum is not
understood completely. Multiple surgical and endoscopic
drainage procedures have been performed to treat these
conditions based on the hypothesis that the minor papilla
is too small to accommodate the volume of pancreatic se-
cretion. In an early report, endoscopic sphincterotomy of
the minor papilla proved to be technically difficult, with
a successful outcome in only 5 of 12 patients, and inef-
fective, with a good outcome in only patient (16). The
data for surgical treatment, drawn from a small number
of series reported by a few surgeons, show a good out-
come in 74% to 93% of patients with pancreatitis after
sphincteroplasty or sphincterotomy of the minor papilla.
Fewer patients, approximately 38%, with the pancreatic
pain syndrome derive benefit from surgery (9-10). On the
other hand, patients with pancreas divisum and chronic
pancreatitis can be effectively treated with resection like
other patients with chronic pancreatitis (8).
Because ofadvances in technique and promising results
of preliminary reports, endoscopic therapy for sympto-
matic pancreas divisum has generated much interest
(17-18). Initially, in our earlier reports, we performed en-
doscopic dilation and stent placement without sphinc-
terotomy in these patients and referred those who had
recurrent or persistent symptoms after endoscopic ther-
apy to (11, 14) surgery. Relief of symptoms after stentENDOSCOPIC STENTING AND SPHINCTEROTOMY 135
Figure 3 Videoendoscopic sequence showing stent placement in the dorsal pancreatic duct via the
minor papilla. (Upper left) the minor papilla, (upper right) cannulation with a 0.035-in guidewire,
(lowerpanels) a straight7 French stentas it is pushed into the dorsal duct, and the guidewire isremoved.
placement into the dorsal duct predicted better clinical
outcome in those patients who eventually underwent
surgery. To achieve definitive therapy without surgery, we
began performing endoscopic sphincterotomy of the
minor papilla. The current report summarizes our recent
experience.
The classification of patients with symptomatic pan-
creas divisum into those withdocumented pancreatitis and
those with pain only has been reported to be important in
predicting the clinical response to both surgical or endo-
scopic drainage (9-10, 13). No pathophysiologic expla-
nation has been offered for the different responses to
therapy between these two groups except the obvious fact
that patients with pancreatitis exhibit definite evidence of
pancreatic disease, whereas in patients with pain only, the
evidence is circumstantial.
We observed clinical improvement with the initial stent
in 71% of the pancreatitis patients and 73% of the pain-
only patients. This decreased with follow-up to 43% and
55%, respectively. Initial clinical response to stenting was
a favorable prognostic sign but did not assure long-term
relief from endoscopic therapy. Comparing our response
rates with those of other published studies is fraught with
difficulty because of different methodology and the sub-
jective nature ofsymptoms. Lans and colleagues reported
a 50% or greater symptomatic improvement in 9 (90%)
of 10 patients with pancreatitis after dorsal duct stenting,
as opposed to only 1 (11%) of9 in the control group (12).
Lehman et al., reported clinical benefit in 13 (76.5%) of
17 patients with pancreatitis treated with stents and
sphincterotomy (13), whereas Barkun and associates re-
lated marked improvement in 9 (45%) of 20 patients
treated with dilation and stenting (19). More recently,
Coleman reported that stenting with or without sphinc-
terotomy was effective in 10 (77%) of 13 of patients with
acute recurrent pancreatitis.
The significant reduction of symptoms in 55% of our
patients with a pancreatic pain syndrome is better than the
27% reported by Lehman et al. (13), or the 20% efficacy
reported by Coleman for endoscopic treatment (20), and
similar to the best surgical results of 56% reported by
Warshaw (9). This finding is limited, however, by lack of136 S.A. COHEN et al.
Figure 4 A radiograph of a C-loop stent in the dorsal pancreatic duct after insertion (the same patient as in Figure and 2).
a control group to determine the placebo effect of sham
endoscopic therapy.
Our results have to be evaluated carefully because the pa-
tients were polled retrospectively concerning their symp-
toms, which has methodologic weaknesses. Optimally,
objective parameters such as narcotic use and hospitaliza-
tions should be measured. Despite these shortcomings, we
believe these results are promising and that pancreas divi-
sum patients with pain deserve careful study. To date, only
one series has compared minor papilla stenting and sphinc-
terotomy versus no therapy in a controlled fashion in this
population of patients (21). It showed that 44% of patients
treated endoscopically clinically improved compared with
only 24% of control patients and a trend towards a reduc-
tion of hospital days required for symptoms.
We were not able to demonstrate a difference in out-
come between patients classified as pancreatitis and pain
only. This lack of difference is bothersome and may be
related to the small number of patients.
The incidence of pancreatitis after endoscopic sphinc-
terotomy was 29%, with 5 mild and moderate. The mean
hospital stay in this study was 2.1 days. There were no seri-
ous complications such as phlegmon, necrosis, pseudocyst,
or sepsis in our series. Direct manipulation of the pancreas
at ERCP is expected to contribute to hyperamylasemia and
possible pancreadtis, but as others have reported, this is usu-
ally not severe (22). These results are in keeping with our
past experience of dorsal duct stenting in more than 90 pa-
tients with symptomatic pancreas divisum (1 l, 14). It must
be emphasized that ERCP is an invasive procedure with a
small but real incidence of severe, even fatal complications.
One case of fatal post-ERCP pancreatitis has been reported
in a patient with pancreas divisum after unsuccessful cannu-
lation (13). This is an inherent risk of the procedure and not
specificallyrelated to treatmentofpancreas divisum. Overall,
endoscopic sphincterotomy of the minor papilla can be per-
formed without prohibitive mortality.
Migration of stents into the dorsal pancreatic duct oc-
curred with 5% of stents (2 of 39). This is similar to the
incidence reportedby Johanson, whofound that 14 (5.2%)
of 267 pancreatic stents migrated proximally. Eleven
(79%) migrated stents were successfully retrieved endo-ENDOSCOPIC STENTING AND SPHINCTEROTOMY 137
Figure5 Videoendoscopic sequence ofadenovo needle knife sphincterotomy ofthe minor papilla.
(Upper left) the minor papilla, (upper right and lower left) cutting with the needle knife
sphincterotome, (lower right) after sphincterotomy.
scopically and (7%) required surgical retrieval. Thus,
migrated stents are usually retrievable with a basket or
balloon but may require surgery for removal (24). One
stent in the current series fractured during its retrieval.
This is unusual; the stent may have been damaged during
sphincterotomy and firmly adherent in the pancreas be-
cause of prolonged placement.
Stent migration was the most serious morbidity in this
series: one patient underwent surgery because of persis-
tent symptoms and a migrated stent, and the patient with
the fractured stent still has a stent in place. To reduce stent
migration, we have modified our pancreatic stents to in-
clude only a single proximal barb and a C-loop in the duo-
denum to prevent inward migration (Figure 4); Geenen
and associates recommend removing the two proximal
barbs from straight pancreatic stents and have reported
that this reduces the incidence of inward migration.
We observed morphologic ductal changes including ec-
tasia and dilation simulating chronic pancreatitis in 89% of
patients with available radiographs. These changes have
been previously reported (24, 27-28) and are probably re-
lated to occlusion of the stent, obstruction of side branches
caused by insufficient number of side holes, and trauma to
the ductal epithelium. This high rate ofductal changes prob-
ably relates to the prolonged stent duration and to the fact
that most stents were occluded at the time of removal, al-
though only halfofthe patients were symptomatic. Stent as-
sociatedpancreatic ductal changes are largely reversible and
have not been shown to be of clinical significance (28). We
speculate that many of these changes would regress if the
pancreatograms were repeated 4 to 6 months after stent re-
moval. Ductal changes may be minimized by leaving the
stents in for shorter periods of time (13) (i.e., less than eight
weeks), varying the lengthofthe stents duringeachexchange
(12), and placing stents with more side holes to allow bet-
ter drainage. Nevertheless, the incidence of ductal changes
are high enough to argue that pancreatic stenting be pru-
dently restricted until more is known.
We conclude that endoscopic stenting and minor papilla
sphincterotomy are technically feasible and may be clini-138 S.A. COHEN et al.
Figure 6 Videoendoscopic sequence of minor papilla sphincterotomy performed with a stent in place.
(Upper panels the needle knife cuts over the stent as a guide in the o’clock orientation, (lower panel)
after completion of the sphincterotomy.
cally effective in symptomatic patients with pancreas divi-
sum. Endoscopic therapy of the pancreas, however, is lim-
ited by complications particularly related to stent migration
and ductal changes. Investigators continue to refine patient
selection, stent design, and duration of stenting. Endoscopic
therapy ofthe pancreas should prudently be restricted to ex-
pert centers where clinical trials are being performed.
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